PXD005536 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Quantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib |
Description | Acquired drug resistance and tumour relapse impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapeutic strategies to overcome drug resistance represents a significant unmet need. Understanding the signalling pathways that drive drug resistance will facilitate the development of new salvage therapies to effectively treat patients with secondary TKI resistance. In this study, we utilise quantitative mass spectrometry to characterise the global phosphoproteomic alterations that accompany the acquisition of resistance to two FDA-approved multi-target TKIs, pazopanib and dasatinib, in the A204 rhabdoid tumour cell line. Our analysis finds that only a limited fraction of the quantified phosphoproteome (<10%) is altered upon the acquisition of drug resistance with pazopanib resistant cells displaying elevated phosphorylation levels in cytoskeletal regulatory pathways and dasatinib resistant cells showing an upregulation of components of the insulin receptor/IGF1-R signalling pathway. Drug response profiling with a targeted panel of small molecule inhibitors rediscovers several previously reported vulnerabilities associated with pazopanib and dasatinib resistance and identifies a new dependency to the second generation HSP90 inhibitor NVP-AUY-922. This study provides a useful resource detailing the candidate signalling determinants of acquired TKI resistance; and reveals a therapeutic approach of inhibiting HSP90 function as a means of salvage therapy to overcome pazopanib and dasatinib resistance. |
HostingRepository | PRIDE |
AnnounceDate | 2024-10-22 |
AnnouncementXML | Submission_2024-10-22_04:38:53.097.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Frank McCarthy |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | phosphorylated residue |
Instrument | LTQ Orbitrap Velos; Q Exactive |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2016-12-09 07:04:10 | ID requested | |
1 | 2017-08-30 00:55:58 | announced | |
⏵ 2 | 2024-10-22 04:39:01 | announced | 2024-10-22: Updated project metadata. |
Publication List
10.1016/j.jprot.2017.08.015; |
Vyse S, McCarthy F, Broncel M, Paul A, Wong JP, Bhamra A, Huang PH, Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J Proteomics, 170():130-140(2018) [pubmed] |
Keyword List
submitter keyword: resistance, dasatinib, pazopanib,A204, phosphoproteomics |
Contact List
Paul Huang |
contact affiliation | Protein Networks, The Institute of Cancer Research, Division of Cancer Biology, 237 Fulham Road, London, SW3 6JB, UK |
contact email | paul.huang@icr.ac.uk |
lab head | |
Frank McCarthy |
contact affiliation | ICR |
contact email | frank.mccarthy@icr.ac.uk |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2017/08/PXD005536 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD005536
- Label: PRIDE project
- Name: Quantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib